1. Sweden Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Biovica International AB Class B

Biovica International AB Class B

0.30
SEK
+0.00
(-0.65%)
-0.25EPS
145.96MMarket Cap
Dec 17Next Earn
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
0.02
0.13
0.03
0.14
0.16
0.06
0.07
0.07
0.09
0.12
0.09
0.06
0.05
Basic EPS, GAAP
-0.37
-0.31
-0.76
-0.94
-1.12
-1.17
-1.27
-1.93
-2.93
-1.97
-0.95
-0.3
-0.25
Free Cash Flow per Basic Share
-0.15
-0.74
-0.86
-1.22
-1.31
-1.23
-1.22
-1.78
-2.58
-1.81
-0.93
-0.27
-0.23
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.43
1.27
4.76
3.83
2.71
3.03
5.9
3.98
2.8
1.06
0.41
0.3
0.23
Tangible Book Value per Share
-0.37
0.31
3.24
2.07
0.74
1.38
4.55
2.68
2.04
0.71
0.16
0.22
0.16
Basic Weighted Avg Shares
19
19
19
19
19
26
31
31
38
63
93
235
284
Sales/Revenue/Turnover
- -
2
1
3
3
2
2
2
3
7
9
13
15
Operating Margin (%)
-1,574.29
-282.89
-2,321.36
-659.9
-731.58
-1,784.26
-2,001.88
-2,997.51
-3,277.9
-1,750.75
-1,022.51
-527.95
-483.21
Depreciation Expense
1
2
2
3
3
4
6
6
8
9
9
8
8
Net Income, GAAP
-7
-6
-15
-18
-22
-30
-39
-60
-110
-125
-88
-70
-72
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-1,534.42
-245.27
-2,328.32
-661.4
-717.34
-1,814.36
-1,900.96
-2,934.13
-3,265.13
-1,712.25
-1,016.52
-522.12
-487.17
Working Capital
-7
-2
61
38
12
33
139
79
96
60
13
62
40
LT Debt
- -
- -
- -
- -
- -
2
1
9
7
4
2
2
3
Total Equity
8
25
92
74
52
78
183
124
139
97
43
86
67
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-36.3
-25.33
-21.78
-34.27
-46.53
-30.27
-39.12
-84.11
-106.11
-125.31
-107.86
-156.59

Capital Structure

SEK

•

in mil. unless spec.
Jan'26
Apr'26
Jul'27
ST Debt
3
3
3
LT Borrowings
- -
- -
- -
LT Finance Leases
2
2
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
292
292
292
Market Capitalization
129
102
146

Working Capital

SEK

•

in mil. unless spec.
Jan'26
Apr'26
Jul'27
Total Current Assets
96
80
60
Cash, Cash Equivalents & STI
88
70
52
Accounts Receivable, Net
3
5
4
Inventories
2
2
2
Total Current Liabilities
18
19
20
Payables & Accruals
- -
- -
- -
ST Debt
3
3
3
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
40.21%
-1.22%
99.82%
Free Cash Flow
19.81%
17.6%
-26.12%
Net Income, GAAP
35.87%
19.8%
-20.27%
Sales/Revenue/Turnover
49.99%
50.57%
55.22%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
2
2
2
2
9
2026
3
3
3
5
13
2027
4
- -
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-0.25
-0.21
-0.22
-0.21
-0.95
2026
-0.18
-0.06
-0.06
-0.07
-0.3
2027
-0.07
- -
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Theis Kipling
Full Time Employees
24
Sector
Health technology
Industry
Biotechnology
Address
Dag HammarskjOelds vAeg 54B Uppsala UP Sweden 752 37
IPO Date
Mar 29, 2017
Website
biovica.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Biovica International AB (publ) specializes in developing and commercializing blood-based biomarker assays aimed at improving monitoring and prediction of cancer therapies. Its core product is DiviTum® TKa, an assay that measures the thymidine kinase 1 (TKa) biomarker to assess cell proliferation in solid tumors, providing oncologists with actionable insights into therapy effectiveness and disease progression. The company offers its assays through a CLIA-certified laboratory mainly across the United States, Europe, and Japan. Additionally, Biovica provides pharmaceutical services including contract testing and biomarker analysis for drug development in oncology, supported by multiple Master Service Agreements (MSAs) with leading pharmaceutical companies. Founded in 2001 and headquartered in Uppsala, Sweden, Biovica operates globally with strong commercial presence notably in the US and key European markets. Recent expansions include a major partnership with Tempus AI in the United States, enabling DiviTum TKa to be offered nationwide through Tempus's extensive oncology sales network, broadening commercial reach significantly. Biovica also entered into a collaboration with Eurobio Scientific, which covers approximately 60% of the European market, leveraging Eurobio’s comprehensive hospital and laboratory network to accelerate adoption across Europe. The company continues to strengthen its Pharma Services segment with new contracts from Tier 1 pharmaceutical companies, enhancing its revenue base and pipeline engagement. In 2025, Biovica launched DiviTum TKa for early breast cancer patients undergoing adjuvant therapy, marking a strategic expansion into a new market segment with potential for up to a fivefold increase in addressable market size, estimated around USD 3 billion annually in key regions. The company completed a fully guaranteed rights issue raising approximately SEK 80 million to fuel growth initiatives and ongoing commercialization efforts. Its financial outlook has improved with increased sales and contract values, with projected breakeven anticipated around 2027-2028 based on analyst consensus. Biovica’s offerings focus on oncology diagnostics and pharmaceutical services, targeting oncologists, pharmaceutical companies, and healthcare providers. The company’s robust partnerships, expanded product applications, and geographical growth are driving its evolution as a key player in blood-based cancer monitoring solutions.